Amyndas Pharmaceuticals S.A.   Report issue

For profit Phase 2
Founded: Philadelphia PA United States (2014)

Organization Overview

First Clinical Trial
2017
NCT03316521
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Amyndas Pharmaceuticals S.A.

Active Ingredients

Drugs in Phase 2 Trials (1)

amy-101 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Gingivitis (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1